Resources from South Chesapeake Psychiatry

Insights on Mental Health

Explore effective treatments for mental health challenges.

Researcher reviewing clinical trial data for novel depression treatment GlyphAllo

A New Wave in Depression Treatment: GlyphAllo Enters Phase 2b for MDD With and Without Anxious Distress

For decades, we've grappled with the challenge of treating major depressive disorder (MDD)—particularly in clients who also experience anxious distress. Add to that the limitations of current treatments, delayed onset of action, and tolerability issues, and it’s no wonder that innovation in this space is urgently needed

Semaglutide injection pen alongside clinician notes on cardiometabolic health

Treatments

min read

Breaking Barriers: How Semaglutide Can Improve Health for Clients with Schizophrenia

A recent randomized clinical trial published in JAMA Psychiatry has shed new light on an important but often overlooked issue: the physical health of individuals living with schizophrenia (Ganeshalingam et al., 2025). While psychiatric treatment focuses on managing symptoms, many clients also face significant health risks related to weight gain, diabetes, and heart disease—much of it driven by the very medications that stabilize their mental health.

Patient discussing generalized anxiety disorder treatment options with a clinician

Medications

min read

Newest Psychiatric Treatments for Generalized Anxiety Disorder (GAD)

There are few drugs that are Food and Drug Administration (FDA) indicated first line for Generalized Anxiety Disorder (GAD). Selective Serotonin Inhibitors (SSRIs) such as Lexapro (escitalopram), approved in 2005, and Paxil (paroxetine), approved in 1999, by the FDA.

Clinician reviewing lumateperone (Caplyta) prescribing data for bipolar depression

Medications

min read

Caplyta in Bipolar Depression: When Efficacy Meets Tolerability

The conversation around lumateperone (Caplyta) in bipolar depression has become more nuanced with new data and, frankly, more complicated in clinical practice. A recent meta-analysis in the Journal of Psychopharmacology confirmed what many of us already knew at the bedside:

Researcher reviewing GM-2505 clinical trial results for major depressive disorder

Medications

min read

GM-2505: A Promising Advancement in the Treatment of Major Depressive Disorder

GM-2505 (bretisilocin) is a short-acting psychedelic-class compound now in late-stage development for major depressive disorder. A look at the early data, AbbVie’s investment, and what it could mean for clients who have not responded to standard antidepressants.

GLP-1 injection pen and healthy meal representing weight loss medication therapy

Medications

min read

A Deep Dive Into GLP-1 Medication for Weight Loss

GLP-1 medications are an effective tool for weight loss, especially when combined with dietary and behavioral changes. These drugs mimic a natural gut hormone, GLP-1, released after eating to help regulate appetite, digestion, and blood sugar. While digestive side effects are common, serious complications are rare but should be monitored.

Content to Help You Navigate Your Journey

Check out our videos where we share helpful tips and insights to support you every step of the way.

Details

Justin Ray, MSN, PMHNP-BC introduces the South Chesapeake Psychiatry channel: mental health topics, new and emerging treatments, and how the mental health landscape really works — one conversation for clinicians and everyday people alike, explained without the jargon. Start here.

Watch Now Read the transcript

Recent Videos